Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center, Phase IB Study of RO7082859 and Atezolizumab (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Profile

An Open-Label, Multi-Center, Phase IB Study of RO7082859 and Atezolizumab (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Atezolizumab (Primary) ; RO 7082859 (Primary) ; Obinutuzumab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 17 Jan 2019 Planned End Date changed from 17 Jun 2023 to 11 May 2021.
    • 17 Jan 2019 Planned primary completion date changed from 17 Jun 2023 to 11 May 2021.
    • 28 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top